MarketPeel
Insider Trading Intelligence
PK

Peter Kaiser

OCUL
CHIEF DEVELOPMENT OFFICER · OCULAR THERAPEUTIX, INC · CIK 0002011869
FILING MIX · LIFETIME33%/67%
BUYS
4
SELLS
8
TOTAL VALUE
$294.6K
COMPANIES
1
ACTIVE SINCE
Oct 2024
HOLDINGS NOW
266,141
AVG SELL PX
$9.71
TRADE KIND
SHOWING 12 / 12
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 12 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Peter Kaiser, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+28.57%+6.81%+0.40%+6.41%+7.33%
14d7+0.00%+15.57%-0.02%+15.59%+18.80%
30d7+28.57%+5.11%+0.63%+4.48%+2.91%
60d7+42.86%+8.72%+2.56%+6.16%+4.23%
90d7+42.86%+3.97%+2.55%+2.44%+2.86%
180d7(1 pending)+66.67%+6.26%+4.97%+9.28%-17.23%
1y7(4 pending)+0.00%+25.57%+19.11%+6.46%+17.82%
2y7(7 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
OCUL · 266,141 shares · as of May 26, 2026
067,980135,959203,939271,91820252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2025
2025
2025
2025
2026
2026
FLOW · 4 buys / 8 sellsCOVERAGE · 7 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
OCUL
OCULAR THERAPEUTIX, INC
SALE10b5-1
10b5-1 plan
2,967$8.20$24.3K266,141May 26, 2026May 28, 2026View →
OCUL
OCULAR THERAPEUTIX, INC
SALE10b5-1
10b5-1 plan
2,810$8.28$23.3K269,108Feb 23, 2026Feb 25, 2026View →
OCUL
OCULAR THERAPEUTIX, INC
PURCHASEGRANT
Stock grant
79,112271,918Jan 2, 2026Jan 6, 2026View →
OCUL
OCULAR THERAPEUTIX, INC
PURCHASEGRANT
Stock grant
240,932240,932Jan 2, 2026Jan 6, 2026View →
OCUL
OCULAR THERAPEUTIX, INC
SALE10b5-1
10b5-1 plan
3,007$12.02$36.1K191,433Nov 24, 2025Nov 26, 2025View →
OCUL
OCULAR THERAPEUTIX, INC
SALE10b5-1
10b5-1 plan
9,653$11.03$106.5K194,440Oct 2, 2025Oct 6, 2025View →
OCUL
OCULAR THERAPEUTIX, INC
SALE10b5-1
10b5-1 plan
3,011$12.04$36.3K204,093Aug 25, 2025Aug 27, 2025View →
OCUL
OCULAR THERAPEUTIX, INC
SALE10b5-1
10b5-1 plan
2,974$7.17$21.3K207,104May 23, 2025May 27, 2025View →
OCUL
OCULAR THERAPEUTIX, INC
SALE10b5-1
10b5-1 plan
3,009$6.87$20.7K210,078Feb 24, 2025Feb 26, 2025View →
OCUL
OCULAR THERAPEUTIX, INC
SALE10b5-1
10b5-1 plan
2,897$9.01$26.1K213,087Nov 25, 2024Nov 27, 2024View →
OCUL
OCULAR THERAPEUTIX, INC
PURCHASEGRANT
Stock grant
100,000215,984Oct 2, 2024Oct 4, 2024View →
OCUL
OCULAR THERAPEUTIX, INC
PURCHASEGRANT
Stock grant
200,000200,000Oct 2, 2024Oct 4, 2024View →
Other insiders · OCUL
Loading peer insiders…
About this filer
CIK 0002011869
ROLE
Chief Development Officer
PRIMARY
OCUL
COMPANIES
1
ACTIVE SINCE
Oct 2024
MARKETPEEL · /INSIDER/0002011869DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback